DOI QR코드

DOI QR Code

BRCA1 Promoter Hypermethylation Signature for Early Detection of Breast Cancer in the Vietnamese Population

  • Truong, Phuong Kim (Department of Biotechnology Applications in Medicine, Faculty of Biotechnology, Ho Chi Minh City Medicine and Pharmacy University) ;
  • Lao, Thuan Duc (Department of Biotechnology Applications in Medicine, Faculty of Biotechnology, Ho Chi Minh City Medicine and Pharmacy University) ;
  • Doan, Thao Phuong Thi (Department of Pathological Anatomy, Faculty of Medicine) ;
  • Huyen, Thuy Ai (Department of Biotechnology Applications in Medicine, Faculty of Biotechnology, Ho Chi Minh City Medicine and Pharmacy University)
  • 발행 : 2014.12.18

초록

Breast cancer, a leading cause of death among women in most countries worldwide, is rapidly increasing in incidence in Vietnam. One of biomarkers is the disruption of the genetic material including epigenetic changes like DNA methylation. With the aim of finding hypermethylation at CpG islands of promoter of BRCA1 gene, belonged to the tumor suppressor gene family, as the biomarker for breast cancer in Vietnamese population, sensitive methyl specific PCR (MSP) was carried out on 115 samples including 95 breast cancer specimens and 20 normal breast tissues with other diseases which were obtained from Ho Chi Minh City Medical Hospital, Vietnam. The result indicated that the frequency of BRCA1 hypermethylation reached 82.1% in the cases (p<0.001). In addition, the DNA hypermethylation of this candidate gene increased the possibility to be breast cancer with high incidence via calculated odd ratios (p<0.05). In conclusion, hypermethylation of this candidate gene could be used as the promising biomarker application with Vietnamese breast cancer patients.

키워드

참고문헌

  1. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J (2000). Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res, 6, 3923-31.
  2. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, et al (2006). Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res, 8, 38.
  3. Chomczynski P, Sacchi N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal Biochem, 162, 156-9.
  4. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P (2004). Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res, 10, 6189-93. https://doi.org/10.1158/1078-0432.CCR-04-0597
  5. Esteller M, Corn PG, Baylin SB, Herman JG (2001). A gene hypermethylation profile of human cancer. Cancer Res, 61, 3225-9.
  6. Evron E, Umbricht CB, Korz D, et al (2001). Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res, 61, 2782-7.
  7. Fang WJ, Zheng Y, Wu LM, et al (2012). Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Asian Pac J Cancer Prev, 13, 1917-21. https://doi.org/10.7314/APJCP.2012.13.5.1917
  8. Hedenfalk I, Duggan D, Chen Y, et al (2001). Gene-expression profiles in hereditary breast cancer. N Engl J Med, 344, 539-48. https://doi.org/10.1056/NEJM200102223440801
  9. Hoang Lan N, Laohasiriwong W, Stewart JF, Tung ND, Coyte PC (2013). Cost of treatment for breast cancer in central Vietnam. Glob Health Action, 6, 18872-81.
  10. Hsu NC, Huang YF, Yokoyama KK, et al (2013). Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer. PLoS One, 8, 56256. https://doi.org/10.1371/journal.pone.0056256
  11. Ibanez de Caceres I, Battagli C, Esteller M, et al. (2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res, 64, 6476-81. https://doi.org/10.1158/0008-5472.CAN-04-1529
  12. Jacot W, Thezenas S, Senal R, et al (2013). BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer, 13, 523. https://doi.org/10.1186/1471-2407-13-523
  13. Kulis M, Esteller M (2010). DNA methylation and cancer. Adv Genet, 70, 27-56. https://doi.org/10.1016/B978-0-12-380866-0.60002-2
  14. Pongtheerat T, Pakdeethai S, Purisa W, Chariyalertsak S, Petmitr S (2011). Promoter methylation and genetic polymorphism of glutathione S-transferase P1 gene (GSTP1) in Thai breastcancer patients. Asian Pac J Cancer Prev, 12, 2731-4.
  15. Ramezani F, Salami S, Omrani MD, Maleki D (2012). CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis. Asian Pac J Cancer Prev, 13, 451-7. https://doi.org/10.7314/APJCP.2012.13.2.451
  16. Tapia T, Smalley SV, Kohen P, et al (2008). Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics, 3, 157-63. https://doi.org/10.4161/epi.3.3.6387
  17. Terada K, Okochi-Takada E, Akashi-Tanaka S, et al (2009). Association between frequent CpG island methylation and HER2 amplification in human breast cancers. Carcinogenesis, 30, 466-71. https://doi.org/10.1093/carcin/bgp021
  18. Xu X, Gammon MD, Zhang Y, et al (2009). BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat, 115, 397-404. https://doi.org/10.1007/s10549-008-0075-5

피인용 문헌

  1. Hypermethylation of TET1 Promoter Is a New Diagnosic Marker for Breast Cancer Metastasis vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.1197
  2. Correlation of CpG Island Methylation of the Cytochrome P450 2E1/2D6 Genes with Liver Injury Induced by Anti-Tuberculosis Drugs: A Nested Case-Control Study vol.13, pp.8, 2016, https://doi.org/10.3390/ijerph13080776
  3. Intention to Receive Breast Cancer Screening and Related Factors of Influence Among Vietnamese Women in Transnational Marriages pp.1682-3141, 2017, https://doi.org/10.1097/jnr.0000000000000210